URGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
URGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. UroGen Pharma's retained earnings for the quarter that ended in Mar. 2024 was $-711.63 Mil.
UroGen Pharma's quarterly retained earnings declined from Sep. 2023 ($-653.33 Mil) to Dec. 2023 ($-679.35 Mil) and declined from Dec. 2023 ($-679.35 Mil) to Mar. 2024 ($-711.63 Mil).
UroGen Pharma's annual retained earnings declined from Dec. 2021 ($-467.32 Mil) to Dec. 2022 ($-577.10 Mil) and declined from Dec. 2022 ($-577.10 Mil) to Dec. 2023 ($-679.35 Mil).
The historical data trend for UroGen Pharma's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Retained Earnings | Get a 7-Day Free Trial | -228.02 | -356.50 | -467.32 | -577.10 | -679.35 |
UroGen Pharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Retained Earnings | Get a 7-Day Free Trial | -607.32 | -631.45 | -653.33 | -679.35 | -711.63 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
UroGen Pharma (NAS:URGN) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Jason Drew Smith | officer: General Counsel | C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540 |
Robinson James A. Jr. | director | 852 WINTER STREET, WALTHAM MA 02451 |
Mark Schoenberg | officer: Chief Medical Officer | C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007 |
Daniel George Wildman | director | 12520 SUNNYDALE DRIVE, WELLINGTON FL 33414 |
Leana Wen | director | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
Dong Kim | officer: Chief Financial Officer | C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540 |
Elizabeth A. Barrett | officer: Chief Executive Officer | C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007 |
Molly Henderson | officer: Chief Financial Officer | 305 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Peter P. Pfreundschuh | officer: CFO | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Stephen Mullennix | officer: COO | C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007 |
Ran Nussbaum | director | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
Stuart Holden | director | C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007 |
Cynthia M Butitta | director | 3165 PORTER DRIVE, PALO ALTO CA 94304 |
Ron Bentsur | director, officer: Chief Executive Officer | 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022 |
Fred E Cohen | director | 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
From GuruFocus
By Business Wire • 01-11-2024
By Business Wire Business Wire • 01-11-2023
By Business Wire Business Wire • 02-15-2023
By Business Wire • 01-17-2024
By Business Wire Business Wire • 05-04-2023
By Business Wire • 11-07-2023
By Business Wire • 10-03-2023
By Business Wire • 09-08-2023
By Business Wire • 07-27-2023
By Business Wire Business Wire • 05-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.